Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation.
Klupp
J
J
Department of Surgery, Virchow Clinics, Humbolt-University Berlin, Germany.
Bechstein
W O
WO
Pratschke
J
J
Tullius
S G
SG
Gebhard
A
A
Lobeck
H
H
Langrehr
J M
JM
Neuhaus
R
R
Neuhaus
P
P
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000453:epidemiology* / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use; D011446:Prospective Studies; D018570:Risk Assessment; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D011239:Prednisolone; D001379:Azathioprine; D016559:Tacrolimus